Terrie Curran is Director of Arcutis Biotherapeutics, Inc.. Currently has a direct ownership of 10,139 shares of ARQT, which is worth approximately $143,061. The most recent transaction as insider was on Nov 11, 2024, when has been sold 8,687 shares (Common Stock) at a price of $10.85 per share, resulting in proceeds of $94,253. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 10.1K
46.14% 3M change
16.71% 12M change
Total Value Held $143,061

Terrie Curran Transaction History

Date Transaction Value Shares Traded Shares Held Form
Nov 11 2024
SELL
Open market or private sale
$94,253 $10.85 p/Share
8,687 Reduced 46.14%
10,139 Common Stock
Jun 14 2024
BUY
Grant, award, or other acquisition
-
10,139 Added 35.0%
18,826 Common Stock
May 31 2023
BUY
Grant, award, or other acquisition
-
4,375 Added 33.49%
8,687 Common Stock
Jun 01 2022
BUY
Grant, award, or other acquisition
-
4,312 Added 50.0%
4,312 Common Stock

Also insider at

PHAT
Phathom Pharmaceuticals, Inc. Healthcare
MYOV
Myovant Sciences Ltd. Healthcare
TC

Terrie Curran

Director
Florham Park, NJ

Track Institutional and Insider Activities on ARQT

Follow Arcutis Biotherapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ARQT shares.

Notify only if

Insider Trading

Get notified when an Arcutis Biotherapeutics, Inc. insider buys or sells ARQT shares.

Notify only if

News

Receive news related to Arcutis Biotherapeutics, Inc.

Track Activities on ARQT